LBTSF News and Press, Almirall Sa Ord From 02/19/24

Almirall obtains exclusive global rights to develop and commercialize NN-8828 for use in several fields, including immune inflammatory dermatological diseases NN-8828 is an IL-21 blocker which inhibits the pathophysiological functions induced by this cytokine in several immune-modulated d...

Almirall’s Full-Year 2023 Results Company revenue growth driven by the strong performance of the European Dermatology business (+17% year-on-year) based on key growth divers and new launches: Ilumetri ® growing sales at 33.5% year-on-year; Klisyri ® strong sales g...

The phase I study will evaluate the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of ALM223 ALM223 has the potential to rebalance the immune system in several autoimmune diseases 1,2 Almirall S.A. (BME: ALM ) , a global pharmaceutical compa...

The multi-target research and development partnership will focus on severe skin diseases The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space In addition to upfront a...

Lebrikizumab is a monoclonal antibody that binds to IL-13 with high affinity, selectively inhibiting its downstream signalling 1-4 Following the European Commission approval, Germany is the first country where lebrikizumab will be available for prescription Lebrikizumab demons...

The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases Almirall S.A. (BME: ALM ) , a global biopharmaceutical company focused on medical dermatology, and Absci Corpo...

2023-11-11 00:59:06 ET Almirall, S.A. (LBTSF) Q3 2023 Earnings Conference Call November 9, 2023, 4:00 AM ET Company Participants Pablo Divasson - Director, Investor Relations and Corporate Communications Carlos Gallardo - Chairman and CEO Mike McClellan - Chief F...

Almirall achieves Net Sales growth of 6.4%, driven by strong European dermatology performance Almirall's European Dermatology business continued to be the driving force behind Almirall's strong performance in the first nine months of 2023, with a growth rate of 15.9% underpinned by the su...

First readout of two-year data from long-term extension study 43rd Annual Fall Clinical Dermatology Conference Almirall S.A. (BME:ALM ), a global biopharmaceutical company focused on medical dermatology, today announced results from the long-term extension study ...

These primary data of the ADvantage study were presented today at EADV Congress A total of 18 lebrikizumab abstracts were disclosed at EADV, including new data on the depth of response at Week 52 and long-term clinically meaningful response Lebrikizumab also demonstrated improveme...